Featured on CNN, ABC, CBS, Bloomberg, Vogue & Forbes this Health & Wellness NASDAQ Brand, Hires Senior Project Manager: Jupiter Wellness, Inc. (NASDAQ: JUPW)
JUPW just Acquired a 3 Million Dollar Firm and Started a 5 Million Dollar Share Buyback
– Developer of CBD Based Treatments for Multiple Skin Care Applications.
– New e-Commerce & Marketing Team with Experienced Industry Veterans.
– JW-300 Treatment Demonstrated Efficacy for Developing Burns (sunburn) in Clinical Trial.
– Acquisition of Ascent Clinical Research Adding $3 Million Annual Revenue Plus EBITDA Contribution.
– Exclusive Worldwide Rights to Patented Shark Repellent Technologies.
– Novel Cannabidiol Aspartame Combination Treatment Significantly Reduces ISGA Score in Atopic Dermatitis.
– Exclusive Worldwide Rights for Unique Formulas Addressing Jellyfish and Man O’ War Stings, Sea Lice, and Swimmer’s Itch with 4 Patents-Pending.
– Clinical Trial of JW-200 for the Treatment of Actinic Keratosis.
– $5.0 Million Share Buyback Program.
Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products. The JUPW clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer.
JUPW generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun™ sunscreen and other wellness brands.
JUPW has built a portfolio of award-winning wellness brands including CaniSun, fitCBD, Jack, Wellness CBD 1937, Black Belt CBD, and Felix Ambrosia, as well prescription therapeutics such as Photosil that have been featured in numerous media outlets including the Today Show, CNN, ABC, CBS, Animal Planet, AdWeek, Bloomberg, The Washington Post, Vogue, BuzzFeed, and Forbes.
As JUPW continues to expand its clinically tested, science-backed wellness, over-the-counter, and prescription product pipeline, the new marketing team is set to drive revenues.
Exclusive Worldwide Rights to Patented Shark Repellent Technologies for the Sun and Skin Market Licensed From Shark Defense Technologies, the Leader in Its Field Featured in Numerous Media Outlets Including Discovery Channel’s Shark Week and Animal Planet
Jupiter Wellness, Inc.(NASDAQ:JUPW) announced the upcoming launch of CaniSun for Shark Defense™, the latest addition to the Company’s reef-friendly sunscreen line. Through a licensing agreement with Shark Defense Technologies LLC, the leading researcher of chemical, electrochemical, and magnetic shark repellents, Jupiter has the exclusive worldwide rights to patents, formulas, and production methods for shark repellent technologies for use in sun and skincare products. While unprovoked shark bites have been rare, incidence is increasing worldwide at hotspots including the U.S., Australia, South Africa, Brazil, Reunion Island, and the Bahamas according to a study published in the peer reviewed journal Ocean & Coastal Management. “The team at Shark Defense Technologies are the outstanding experts and innovators in the emerging field of shark repellent technologies, and we are pleased to collaborate with them to not only launch a sunscreen line with their technology, but we also plan to work together to further advance and develop additional formulations and IP. CaniSun for Shark Defense™ is a perfect addition to our growing line of sun and skin care products which also includes our recently launched NoStingz jellyfish protective sunscreen,” stated Jupiter CEO Brian John. “We plan to launch CaniSun for Shark Defense™ in Q3 2022.”
About Shark Defense Technologies
Shark Defense Technologies; http://www.sharkdefense.com/ is the leading researcher of chemical, electrochemical, and magnetic shark repellents. Its primary mission is to research and develop shark bycatch reduction devices. Its secondary mission is to research and develop shark repellents for rescue operations, aquaculture, and alternatives to shark netting. Shark Defense began as the humble Oak Ridge Shark Lab in northern New Jersey and was founded in September 2001 by Eric and Jean Stroud. Its early work sought to research the existence of trace chemical messengers in elasmobranchs and to develop a series of highly selective chemical shark repellents using state-of-the-art analytical and synthesis techniques. Many successes in this initial research effort have led to new discoveries in shark repellent technologies, particularly for bycatch reduction.
CBD Caring is a division of Jupiter Wellness Inc.(NASDAQ JUPW).
Jupiter wellness is a CBD-based pharmaceuticals company with 4 significant treatments in skin health for eczema, skin cancer, burns and herpes that are patented or patent pending in various stages of clinical trials. We use that same proprietary science and technology to develop all our consumer products brands.
CBD Caring & Jupiter Wellness are committed to helping you derive all of the wide-ranging physical and mental benefits of its products by providing you the highest quality ingredients in convenient, easy-to-use products designed for your everyday life. Our products are third-party tested and backed by science.
JW-300 Demonstrated Efficacy in the Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo-Controlled Clinical Trial
Jupiter Wellness, Inc. (NASDAQ:JUPW) will present data for Jupiter’s JW-300, a cannabidiol topical treatment for first degree burns, at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference to take place May 11-15, 2022 in Nashville, Tennessee.
In a clinical trial of 36 patients, a controlled area of skin was exposed to UV irradiation. The percentage of subjects who experienced burns (measured by erythema) in patients treated with JW-300 was significantly lower (p=0.047) than in subjects who received the placebo lotion. The percent of subjects who were burned in the placebo arm was 61% compared to 27% in patients treated with JW-300. In addition, in patients (n=18) treated with JW-300, the average erythema score was 0.388 after radiation compared to 0.722 in the placebo arm (n=18).
Dr Glynn Wilson, Chief Scientist of Jupiter Wellness, commented, “These statistically significant results demonstrate JW-300’s potential as either a prescription or over-the-counter topical cream to help prevent sunburn and its more harmful consequences such as skin cancer. We look forward to presenting these important data to leading dermatology and aesthetic medicine physicians at SCALE.”
Jupiter CEO Brian John added, “JW-300 complements our current over-the-counter skincare products including CaniSun™ as well as our prescription product Photocil™, serving a large market that needs more effective solutions.”
Jupiter Wellness to Offer Clinical Research Services with Acquisition of Ascent Clinical Research: $3 Million Annual Revenue & EBITDA Contribution to Jupiter
IN A BID TO EXPAND JUPITER WELLNESS’S RESEARCH CAPABILITIES AND ENTER THE LUCRATIVE CRO BUSINESS, JUPITER WELLNESS ACQUIRED THE ASSETS OF ASCENT CLINICAL RESEARCH
Jupiter Wellness, Inc. (NASDAQ:JUPW) announced it has concluded an Asset Purchase Agreement with Ascent Clinical Research, Inc. through which it has acquired certain clinical assets including clinical trial research contracts worth $3 million in annual revenues for a purchase price of 5% royalties on future net revenues generated by the assets.
“This strategic asset purchase agreement adds immediate revenues to Jupiter in Q2 2022 and contributes positively towards EBITDA with no upfront cash or stock acquisition cost to our company. The acquired contracts and related assets enhance Jupiter’s position as a research and development powerhouse while allowing us to enter the lucrative clinical research organization business,” stated Jupiter CEO Brian John.
- JUPW Presents JW-300 Topical Burn Treatment at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference
JUPW has presented its JW-300, a cannabidiol topical treatment for first degree burns, at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference held May 11-15, 2022 in Nashville.
The results demonstrate JW-300’s potential as either a prescription or over-the-counter topical cream to help prevent sunburn and its consequences including skin cancer.
- JUPW to Offer Clinical Research Services with Acquisition of Ascent Clinical Research: $3 Million Annual Revenue & EBITDA Contribution
On April 27th JUPW announced it has concluded an Asset Purchase Agreement with Ascent Clinical Research, Inc. through which it has acquired certain clinical assets including clinical trial research contracts worth $3 million in annual revenues for a purchase price of 5% royalties on future net revenues generated by the assets. This asset purchase agreement adds immediate revenues to JUPW in Q2 2022 and contributes positively towards EBITDA with no upfront cash or stock acquisition cost.
- JUPW Appoints E-Commerce & Marketing Team to Drive Sales of its Growing Portfolio of Proprietary Health and Wellness Brands
- JUPW to Launch CaniSun for Shark Defense Sunscreen with Patented Shark Repellents
On April 7th JUPW announced the upcoming launch of CaniSun for Shark Defense™, the latest addition to the Company’s reef-friendly sunscreen line. Through a licensing agreement with Shark Defense Technologies LLC, the leading researcher of chemical, electrochemical, and magnetic shark repellents, JUPW has the exclusive worldwide rights to patents, formulas, and production methods for shark repellent technologies for use in sun and skincare products.
- Novel Cannabidiol Aspartame Combination Treatment (JW-100) Significantly Reduces ISGA Score in Atopic Dermatitis: Results from a Randomized Double-Blinded Placebo-Controlled Interventional Study
On April 6th JUPW announced the publication of clinical study results to investigate the safety and efficacy of JW-100, its proprietary lotion formulation for the treatment of atopic dermatitis (eczema) in the Journal of Cosmetic Dermatology, Vol. 21, Issue 4, April 2022, pp: 1647-1650.
- JUPW Launches NoStingz Jellyfish Protective Sunscreen Backed by Patent-Pending Formula in $13 B Sunscreen Market
On April 5th JUPW announced the launch of NoStingz, a proprietary line of sunscreen designed to protect against jellyfish and man o’ war stings, sea lice, and swimmer’s itch all while continuing to protect ocean lovers’ skin from UVA/UVB in a range of SPFs. JUPW has signed a license agreement with Shark Defense Technologies for the exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds including 4 patents pending. The agreement includes future collaboration to develop and refine additional formulas.
For more on The JUPW NoStingz product or to purchase visit: https://canisun.com/shop/nostingz-your-barrier-of-protection-from-sun-sea/
- JUPW Completes Enrollment in Double-Blind Placebo-Controlled Clinical Trial of JW-200 for the Treatment of Actinic Keratosis
On February 18th JUPW announced it has completed recruitment in its clinical trial of JW-200 for the treatment of actinic keratosis (AK), a common form of pre-cancerous growths that typically present as thick scaly lesions on sun exposed skin. If left untreated, up to 15.1% of patients with 10 or more AK lesions will develop keratinocyte carcinoma.
- JUPW Board Approval of $5.0 Million Share Buyback Program
On January 25th JUPW announced it its board of directors approved a $5.0 million share buyback program which expires on June 30, 2022. Under the Share Buyback Program, shares of JUPW common stock may be repurchased periodically in open market or privately negotiated transactions.
For additional information on Jupiter Wellness, Inc. (JUPW) visit www.jupiterwellnessinc.com.